Nine months' subcutaneous therapy with synthetic growth hormone releasing factor in children with short stature.

Hümmelink R, Rohwedder R, Sippell WG

Acta paediatrica Scandinavica. Supplement1 Jan 1987Cited by 10 (Europe PMC)

PMID2886000DOI10.1111/j.1651-2227.1987.tb17098.xPepBankPUB-02886000

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanNon-randomized trialEfficacy outcome
In nine boys with short stature, the stadiometric growth rate over the whole study period rose from 4.92 to 5.97 cm/year, which was not statistically significant.
In plain wordsIn nine short boys, yearly growth measured by stadiometer rose from 4.92 to 5.97 cm, but the change was not statistically significant.
Peptide
Sermorelin
Outcome
No significant changeStadiometric growth rate over 11 months
Study
n = 9
Outcome group
Linear growth · Endocrine and hormones
Studied dose
3-4 micrograms/kg b.d. or once daily, then 8-10 micrograms/kg once daily · subcutaneous · 11 months including treatment-free intervalsAs given in this study (human).
Measurements
Stadiometric growth rate
4.92 cm/year
before
Stadiometric growth rate
5.97 cm/year
whole study period
Source sentences
Summary
Stadiometric growth rate, determined over the whole study period of 11 months including the treatment-free intervals, increased from 4.92 cm/year to 5.97 cm/year (p greater than 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
The growth promoting potential of GRF(1-29)NH2 was studied in nine boys with short stature over three periods of 3 months.
Report a problemFND-0288600001
02HumanNon-randomized trialEfficacy outcome
In nine boys with short stature, the knemometric lower leg growth rate rose from 0.28 to 0.35 mm/week during low-dose once-daily GRF.
In plain wordsIn nine short boys, lower leg growth measured by knemometer rose from 0.28 to 0.35 mm per week on a low daily dose.
Peptide
Sermorelin
Outcome
IncreaseKnemometric growth rate, low-dose once-daily period
Study
n = 9
Outcome group
Linear growth · Endocrine and hormones
Studied dose
3-4 micrograms/kg once daily · subcutaneous · 3 monthsAs given in this study (human).
Measurements
Knemometric growth rate
0.28 mm/week
before therapy
Knemometric growth rate
0.35 mm/week
one injection/day, low dose
Source sentences
Summary
Mean knemometric growth rates increased from 0.28 mm/week before therapy, to 0.35 mm/week during the one injection/day period at low dose, to 0.39 mm/week (p less than 0.05) during the b.d. period, and to 0.40 mm/week during the last 3 months of high-dose GRF given once daily.(ABSTRACT TRUNCATED AT 250 WORDS)
1 context sentence(design, population, supporting numbers)
Summary · context
The growth promoting potential of GRF(1-29)NH2 was studied in nine boys with short stature over three periods of 3 months.
Report a problemFND-0288600002
03HumanNon-randomized trialEfficacy outcome
In nine boys with short stature, the knemometric growth rate rose to 0.39 mm/week (p less than 0.05) during twice-daily GRF.
In plain wordsIn nine short boys, lower leg growth measured by knemometer rose to 0.39 mm per week on a twice-daily dose.
Peptide
Sermorelin
Outcome
IncreaseKnemometric growth rate, twice-daily period
Study
n = 9
Outcome group
Linear growth · Endocrine and hormones
Studied dose
3-4 micrograms/kg twice daily · subcutaneous · 3 monthsAs given in this study (human).
Measurements
Knemometric growth rate
0.39 mm/week
b.d. period
Source sentences
Summary
Mean knemometric growth rates increased from 0.28 mm/week before therapy, to 0.35 mm/week during the one injection/day period at low dose, to 0.39 mm/week (p less than 0.05) during the b.d. period, and to 0.40 mm/week during the last 3 months of high-dose GRF given once daily.(ABSTRACT TRUNCATED AT 250 WORDS)
1 context sentence(design, population, supporting numbers)
Summary · context
The growth promoting potential of GRF(1-29)NH2 was studied in nine boys with short stature over three periods of 3 months.
Report a problemFND-0288600003
04HumanNon-randomized trialEfficacy outcome
In nine boys with short stature, the knemometric growth rate rose to 0.40 mm/week during the last 3 months of high-dose once-daily GRF.
In plain wordsIn nine short boys, lower leg growth measured by knemometer rose to 0.40 mm per week on a high daily dose.
Peptide
Sermorelin
Outcome
IncreaseKnemometric growth rate, high-dose once-daily period
Study
n = 9
Outcome group
Linear growth · Endocrine and hormones
Studied dose
8-10 micrograms/kg once daily · subcutaneous · 3 monthsAs given in this study (human).
Measurements
Knemometric growth rate
0.4 mm/week
high-dose once daily
Source sentences
Summary
Mean knemometric growth rates increased from 0.28 mm/week before therapy, to 0.35 mm/week during the one injection/day period at low dose, to 0.39 mm/week (p less than 0.05) during the b.d. period, and to 0.40 mm/week during the last 3 months of high-dose GRF given once daily.(ABSTRACT TRUNCATED AT 250 WORDS)
1 context sentence(design, population, supporting numbers)
Summary · context
The growth promoting potential of GRF(1-29)NH2 was studied in nine boys with short stature over three periods of 3 months.
Report a problemFND-0288600004

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
10 Oct 2026, 10:21 UTC
Study results updated
Version 1
9 Oct 2026, 03:13 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.